Article
Drug Resistance Profile and Clinical Features for Hepatitis C Patients Experiencing DAA Failure in Taiwan.
Viruses - 17 Nov 2021
Hong Chun-Ming, Lin You-Yu, Liu Chun-Jen, Lai Ya-Yun, Yeh Shiou-Hwei, Yang Hung-Chih, Kao Jia-Horng, Hsu Shih-Jer, Huang Yi-Hsiang, Yang Sheng-Shun, Kuo Hsing-Tao, Cheng Pin-Nan, Yu Ming-Lung, Chen Pei-Jer
Abstract excerpt
About 4% of the population in Taiwan are seropositive for anti-HCV Ab and 70% with HCV RNA. To address this high chronic hepatitis C disease load, Taiwan National Health Insurance started reimbursing genotype-specific DAAs in 2017 and pangenotype DAAs in mid-2018. With a 97% SVR12 rate, there were still 2-3% of patients that failed to clear HCV. To understand the causes of DAA failure in Taiwan, we conducted a...
Read the complete abstract on PubMedTopics
Share this publication in a Topic to start or enrich a Post.